Response Genetics Stock Today
| RGDXQ Stock | USD 0.0001 0.00 0.00% |
PerformanceWeakest
| Odds Of DistressStrong
|
Response Genetics is selling at 1.0E-4 as of the 24th of December 2025; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 1.0E-4. Response Genetics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 24th of November 2025 and ending today, the 24th of December 2025. Click here to learn more.
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. The company has 38.8 M outstanding shares of which 78.1 K shares are at this time shorted by private and institutional investors with about 0.31 days to cover all short positions. More on Response Genetics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Response Pink Sheet Highlights
| Business Concentration | Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) |
Response Genetics [RGDXQ] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 116. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Response Genetics's market, we take the total number of its shares issued and multiply it by Response Genetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Response Genetics classifies itself under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 38.8 M outstanding shares of which 78.1 K shares are at this time shorted by private and institutional investors with about 0.31 days to cover all short positions.
Response Genetics has accumulated about 1.73 M in cash with (13.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Response Genetics Probability Of Bankruptcy
Response Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Response Genetics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Additional Tools for Response Pink Sheet Analysis
When running Response Genetics' price analysis, check to measure Response Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Response Genetics is operating at the current time. Most of Response Genetics' value examination focuses on studying past and present price action to predict the probability of Response Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Response Genetics' price. Additionally, you may evaluate how the addition of Response Genetics to your portfolios can decrease your overall portfolio volatility.